AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8936350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (in subgroup with disease duration of at least 2 years)
Number of subjects: 60
Study 8936350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup with disease duration of at least 2 years)
Number of subjects: 60
Study 1397668 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Number of subjects: 73
Study 1397668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 3887100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (5 mg/d)
Number of subjects: 19
Study 3887100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31079600 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol SR (Pletaal SR Cap.)
Number of subjects: 30
Study 31079600 — intervention group
Group type: COMPARATOR
Intervention: cilostazol CR (Cilostan CR Tab.)
Number of subjects: 30
Study 31079600 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol SR
Number of subjects: 30
Study 28251920 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote nonpainful electrical upper arm skin stimulation (200-μs, 150-μs, and 100-μs pulse width stimuli)
Number of subjects: 71
Study 28251920 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote nonpainful electrical upper arm skin stimulation (200-μs stimulation protocol)
Number of subjects: 71
Study 28251920 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote nonpainful electrical upper arm skin stimulation
Number of subjects: 71
Study 28251920 — intervention group
Group type: COMPARATOR
Intervention: Sham stimuli
Number of subjects: 71
Study 25239965 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspectorate's supervision programme (A)
Number of subjects: 233
Study 25239965 — intervention group
Group type: COMPARATOR
Intervention: Assessment with a questionnaire (B)
Number of subjects: 233
Study 25239965 — intervention group
Group type: COMPARATOR
Intervention: Site visit assessment (C)
Number of subjects: 233
Study 22008097 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphyseal donor defects filled with bone substitute
Number of subjects: 26
Study 22008097 — intervention group
Group type: COMPARATOR
Intervention: Unfilled symphyseal donor defects
Number of subjects: 26
Study 21799772 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyantigenic whole cell lysate (WCL)
Number of subjects: 979
Study 21799772 — intervention group
Group type: COMPARATOR
Intervention: No detectable baseline IFN-γ responses
Number of subjects: 979
Study 21799772 — intervention group
Group type: COMPARATOR
Intervention: 0 baseline IFN-γ responses
Number of subjects: 979
Study 21799772 — intervention group
Group type: COMPARATOR
Intervention: 1 baseline IFN-γ response
Number of subjects: 979
Study 21799772 — intervention group
Group type: COMPARATOR
Intervention: 2 baseline IFN-γ responses
Number of subjects: 979
Study 21799772 — intervention group
Group type: COMPARATOR
Intervention: 3 baseline IFN-γ responses
Number of subjects: 979
Study 21799772 — intervention group
Group type: EXPERIMENTAL
Intervention: Each increment in the number of detectable baseline IFN-γ responses
Number of subjects: 979
Study 19489942 — intervention group
Group type: EXPERIMENTAL
Intervention: bosentan
Number of subjects: 14
Study 19489942 — intervention group
Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 14
Study 16757445 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet group
Number of subjects: 40
Study 16757445 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face group
Number of subjects: 40
Study 15557943 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with midazolam and placebo pharyngeal spray (midazolam group)
Number of subjects: 252
Study 15557943 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo sedation and lidocaine pharyngeal spray (lidocaine group)
Number of subjects: 252
Study 15557943 — intervention group
Group type: COMPARATOR
Intervention: Placebo sedation and placebo pharyngeal spray (placebo group)
Number of subjects: 252
Study 15557943 — intervention group
Group type: COMPARATOR
Intervention: No intravenous cannula/pharyngeal spray (control group)
Number of subjects: 252
Study 11232742 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified digital inclinometer
Number of subjects: 39
Study 9275135 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium (0.5 mg) plus salbutamol (2.5 mg) (Combivent)
Number of subjects: 338
Study 9275135 — intervention group
Group type: COMPARATOR
Intervention: Nebulized salbutamol (2.5 mg) alone
Number of subjects: 338
Study 7878598 — intervention group
Group type: COMPARATOR
Intervention: Single dose of lithium (1.68 mg)
Number of subjects: 16
Study 7878598 — intervention group
Group type: COMPARATOR
Intervention: Repetitive doses of lithium (0.56 mg twice a day for 11 days)
Number of subjects: 16
Study 7878598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3067180 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied tretinoin ophthalmic ointment (0.01%)
Number of subjects: 161
Study 3067180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 2248069 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 30
Study 2248069 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 30
Study 4594581 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 to 1,000 mug GHRIH administered by constant infusion over 75 minutes
Number of subjects: 8
Study 4594581 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mug GHRIH administered by constant infusion
Number of subjects: 8
Study 4594581 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mug GHRIH administered by constant infusion
Number of subjects: 8
Study 4594581 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mug GHRIH injected by intravenous, subcutaneous, and intramuscular routes
Number of subjects: 8
Study 4594581 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mug GHRIH injected intramuscularly in 2 ml of 16% gelatin
Number of subjects: 8
Study 4594581 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg GHRIH in 1 ml of arachis oil
Number of subjects: 8
Study 4594581 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mug GHRIH during oral 50-g glucose tolerance test
Number of subjects: 8
Study 4594581 — intervention group
Group type: COMPARATOR
Intervention: Saline during oral 50-g glucose tolerance test
Number of subjects: 8
Study 31605307 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y (RY) group
Number of subjects: 180
Study 31605307 — intervention group
Group type: COMPARATOR
Intervention: Billroth I group
Number of subjects: 180
Study 31605307 — intervention group
Group type: COMPARATOR
Intervention: Billroth II group
Number of subjects: 180
Study 28578592 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive minocycline (200 mg/day)
Number of subjects: 71
Study 25948479 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based telerehabilitation program in addition to standard cardiac rehabilitation
Number of subjects: 140
Study 25948479 — intervention group
Group type: COMPARATOR
Intervention: standard cardiac rehabilitation alone
Number of subjects: 140
Study 23828329 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal supplement composed of Curcuma longa and Boswellia serrata
Number of subjects: 16
Study 23828329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21768611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 98
Study 21768611 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 98
Study 19493983 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with parents about sexuality
Number of subjects: 14944
Study 19493983 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with other adult family members about sexuality
Number of subjects: 14944
Study 19493983 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with teachers about sexuality
Number of subjects: 14944
Study 19493983 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with parents in Dar es Salaam
Number of subjects: 14944
Study 19493983 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication silence in South African sites
Number of subjects: 14944
Study 19493983 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status and communication
Number of subjects: 14944
Study 19493983 — intervention group
Group type: EXPERIMENTAL
Intervention: Explained variation in communication across sites
Number of subjects: 14944
Study 17059514 — intervention group
Group type: EXPERIMENTAL
Intervention: Half elemental diet
Number of subjects: 51
Study 17059514 — intervention group
Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 51
Study 15243279 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone (2.5mg/day)
Number of subjects: 100
Study 15243279 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 11349008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 372
Study 11349008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 11349008 — intervention group
Group type: COMPARATOR
Intervention: Genotype CC
Number of subjects: 372
Study 11349008 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype CT
Number of subjects: 372
Study 11349008 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype TT
Number of subjects: 372
Study 11349008 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype TT or CT
Number of subjects: 372
Study 11349008 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype progression
Number of subjects: 372
Study 9754458 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 or 21 mm SJM aortic valves (Group 1)
Number of subjects: 88
Study 9754458 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 or 25 mm SJM aortic valves (Group 2)
Number of subjects: 88
Study 7924451 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiconazole nitrate lotion, 1 percent, used once or twice daily
Number of subjects: 410
Study 7924451 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 410
Study 3122700 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 27
Study 3122700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride
Number of subjects: 27
Study 3122700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine sulfate
Number of subjects: 27
Study 3122700 — intervention group
Group type: EXPERIMENTAL
Intervention: Clorgiline
Number of subjects: 27
Study 29737801 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy education based on the Health Belief Model for 3 months followed by a 24-week follow-up
Number of subjects: 240
Study 29737801 — intervention group
Group type: COMPARATOR
Intervention: Conventional dietary counseling
Number of subjects: 240
Study 27514696 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous spacer (ISP) implantation
Number of subjects: 53
Study 27514696 — intervention group
Group type: COMPARATOR
Intervention: Decompressive laminectomy (DL)
Number of subjects: 53
Study 26003434 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Behavior Therapy (TBT)
Number of subjects: 96
Study 26003434 — intervention group
Group type: COMPARATOR
Intervention: Control psychotherapy
Number of subjects: 96
Study 23410234 — intervention group
Group type: EXPERIMENTAL
Intervention: Guttman-type scale of 'basic mobility'
Number of subjects: 1164
Study 23410234 — intervention group
Group type: EXPERIMENTAL
Intervention: Guttman-type scale of 'walking'
Number of subjects: 1164
Study 23410234 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed scales
Number of subjects: 1164
Study 20578385 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy manipulation of acupuncture
Number of subjects: 9
Study 20578385 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle manipulation of acupuncture
Number of subjects: 9
Study 20578385 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 9
Study 20578385 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (acupuncture or other therapy on the upper extremities)
Number of subjects: 9
Study 18251359 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (0.2 mg)
Number of subjects: 25
Study 18251359 — intervention group
Group type: COMPARATOR
Intervention: hCG (5,000 IU)
Number of subjects: 25
Study 17409969 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day)
Number of subjects: 342
Study 14614665 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone and proguanil (20 and 8 mg/kg of body weight, respectively, administered once daily for 3 days)
Number of subjects: 200
Study 14614665 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine (10 mg/kg of body weight, once daily for 3 days)
Number of subjects: 200
Study 14614665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 11590579 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9462194 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 68
Study 9462194 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 68
Study 9462194 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 and C-reactive protein on day 0, together with either TNF alpha on day 1 or C-reactive protein on day 2
Number of subjects: 68
Study 7930011 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention sutures
Number of subjects: 75
Study 7930011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensed Silastic-Dacron strips
Number of subjects: 75
Study 7930011 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 75
Study 2834931 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 32
Study 2834931 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine
Number of subjects: 32
Study 2834931 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 32
Study 31176480 — intervention group
Group type: EXPERIMENTAL
Intervention: Haraguchi Type II PM ankle fractures
Number of subjects: 73
Study 31176480 — intervention group
Group type: COMPARATOR
Intervention: Haraguchi Type III PM ankle fractures
Number of subjects: 73
Study 28419248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously every 2 weeks
Number of subjects: 821
Study 28419248 — intervention group
Group type: COMPARATOR
Intervention: Everolimus 10 mg tablet orally once daily
Number of subjects: 821
Study 28419248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (Japanese subgroup)
Number of subjects: 821
Study 28419248 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (Japanese subgroup)
Number of subjects: 821
Study 28419248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (Japanese patients)
Number of subjects: 821
Study 28419248 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (Japanese patients)
Number of subjects: 821
Study 26665291 — intervention group
Group type: EXPERIMENTAL
Intervention: O-R power toothbrush (Oral-B Professional Care 1000 with CrossAction brush head)
Number of subjects: 148
Study 26665291 — intervention group
Group type: COMPARATOR
Intervention: Sonic toothbrush (Sonicare DiamondClean with standard brush head)
Number of subjects: 148
Study 23890405 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine formulations (AS03(A), AS03(B), AS03(C) with varying tocopherol and MPL doses)
Number of subjects: 400
Study 23890405 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03(A)-MPL25, AS03(B)-MPL25, AS03(B)-MPL50
Number of subjects: 400
Study 23890405 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Number of subjects: 400
Study 23890405 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine
Number of subjects: 400
Study 21145181 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 75
Study 21145181 — intervention group
Group type: COMPARATOR
Intervention: Standard (Std) intake interview
Number of subjects: 75
Study 19576643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastitis control plan implementation
Number of subjects: 0
Study 19576643 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased trial sizes
Number of subjects: 0
Study 17544886 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (0.35 mg/kg bolus; 0.15 mg/kg before aortic cross-clamping and 0.2 mg/kg in cardioplegic solution)
Number of subjects: 34
Study 17544886 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 15209181 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (four-week program with one-year follow-up)
Number of subjects: 236
Study 15209181 — intervention group
Group type: COMPARATOR
Intervention: Continued care within primary care (control group)
Number of subjects: 236
Study 11472288 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB (>35 degrees C) in diabetic patients (Group DN, n=8)
Number of subjects: 16
Study 11472288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (32 degrees C) in diabetic patients (Group DH, n=8)
Number of subjects: 16
Study 11472288 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB in age-matched non-diabetic patients (Group CN, n=8)
Number of subjects: 16
Study 11472288 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic CPB in age-matched non-diabetic patients (Group CH, n=8)
Number of subjects: 16
Study 9813958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 9813958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7726876 — intervention group
Group type: COMPARATOR
Intervention: HemoTec
Number of subjects: 113
Study 7726876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemochron
Number of subjects: 113
Study 2527401 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg clodronate infused intravenously daily for 10 days
Number of subjects: 80
Study 2527401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 300 mg clodronate dissolved in 500 ml saline for 2 weeks
Number of subjects: 80
Study 2527401 — intervention group
Group type: COMPARATOR
Intervention: 500 ml saline (control) for 2 weeks
Number of subjects: 80
Study 2527401 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 1200 mg clodronate for 2 weeks
Number of subjects: 80
Study 2527401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 100 mg clodronate for 2 weeks
Number of subjects: 80
Study 2527401 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with 1200 mg clodronate/day for at least 6 weeks after a 2-week intravenous treatment course
Number of subjects: 80
Study 2527401 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine biochemical examination during and after treatment
Number of subjects: 80
Study 779056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcerone (tripotassium di-citrato bismuthate) for 6 weeks
Number of subjects: 50
Study 779056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30579753 — intervention group
Group type: EXPERIMENTAL
Intervention: Selamectin plus sarolaner
Number of subjects: 405
Study 30579753 — intervention group
Group type: COMPARATOR
Intervention: Imidacloprid plus moxidectin
Number of subjects: 405
Study 28287819 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding Motivation Program (BMP)
Number of subjects: 100
Study 28287819 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 26231301 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial caries removal (PCR)
Number of subjects: 48
Study 26231301 — intervention group
Group type: COMPARATOR
Intervention: Total caries removal (TCR)
Number of subjects: 48
Study 23436842 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-based tube current modulation
Number of subjects: 80
Study 23436842 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast shield
Number of subjects: 80
Study 23436842 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast shield plus organ-based tube current modulation
Number of subjects: 80
Study 23436842 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 22005142 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing interviews for medication therapy management (MTM) services
Number of subjects: 43
Study 19277992 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (22 mg Zn d(‐1) as zinc gluconate)
Number of subjects: 47
Study 19277992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 17292364 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 0
Study 17292364 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 0
Study 15277927 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 500 micrograms with sufentanil 10 micrograms
Number of subjects: 125
Study 15277927 — intervention group
Group type: COMPARATOR
Intervention: Epidural sufentanil 20 micrograms
Number of subjects: 125
Study 15277927 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 250 micrograms with sufentanil 10 micrograms
Number of subjects: 125
Study 15277927 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 750 micrograms with sufentanil 10 micrograms
Number of subjects: 125
Study 11574085 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded interviews
Number of subjects: 132
Study 11574085 — intervention group
Group type: COMPARATOR
Intervention: Unblinded interviews
Number of subjects: 132
Study 9762801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean dPoes,max/dt at the start of treadmill walks
Number of subjects: 6
Study 9762801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean dPoes,max/dt at the finish of treadmill walks
Number of subjects: 6
Study 8736322 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate at 1 microgram/ml
Number of subjects: 0
Study 8736322 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate at 10 micrograms/ml
Number of subjects: 0